NCT03547024 - A Study in Healthy Participants to Evaluate the Effects of Multiple Doses of JNJ-55308942 on Cytochrome P450 Substrate Activity and on the Pharmacokinetics of Levonorgestrel/Ethinyl Estradiol | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 8, 2018

Primary Completion Date

August 30, 2018

Study Completion Date

August 30, 2018

Conditions

Healthy

Interventions

DRUG

JNJ-55308942 High Dose

Participants will receive high dose of JNJ-55308942 orally once daily.

DRUG

JNJ-55308942 Low Dose

Participants will receive low dose of JNJ-55308942 orally once daily.

DRUG

Levonorgestrel/Ethinyl Estradiol Fixed Dose combination (FDC)

Participants will receive 0.150 milligram (mg) levonorgestrel and 0.030 mg ethinyl estradiol FDC tablet orally.

DRUG

Drug Cocktail:Midazolam (2mg)/Omeprazole (20mg)/Dextromethorphan (30mg)

Participants will receive single dose of drug cocktail consisting of midazolam (2 mg), dextromethorphan (30mg) and omeprazole (20 mg) orally.

Trial Locations (1)

Clinical Pharmacology Unit, Merksem